GlassScriptPhysician profile
Suresh K Didwania
NPI 1093777880
$8,873.46
in general payments reported to CMS, 2019-2025
48 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,601 · 2020: $1,194 · 2021: $1,386 · 2022: $1,632 · 2023: $1,473 · 2024: $1,314 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,886 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,885.79 |
| Education | $176.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $830.74 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $775.73 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $647.25 | 2019-2025 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $574.54 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $466.04 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $458.28 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $405.92 | 2021-2024 | Linzess, Viberzi, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $369.78 | 2021-2024 | |
| Glaxosmithkline, LLC. | $364.12 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $353.67 | 2019-2024 | Mounjaro, Jardiance |
| Amgen INC. | $322.72 | 2019-2024 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $314.11 | 2019-2024 | Veozah, Myrbetriq |
| Sunovion Pharmaceuticals INC. | $306.77 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $244.16 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.87 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Didwania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.